A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

被引:9
|
作者
Nicum, Shibani [1 ,9 ]
Roberts, Corran [2 ]
Boyle, Lucy [3 ]
Kopijasz, Sylwia [3 ]
Gourley, Charlie [4 ]
Hall, Marcia [5 ]
Montes, Ana [6 ]
Poole, Christopher [7 ]
Collins, Linda [3 ]
Schuh, Anna [1 ]
Dutton, Susan J. [2 ,8 ]
机构
[1] Oxford Univ Hosp NHS Trust, Oxford, England
[2] Univ Oxford, Ctr Stat Med, Oxford, England
[3] Univ Oxford, Dept Oncol, OCTO, Oxford, England
[4] Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland
[5] East & North Hertfordshire NHS Trust, Mt Vernon Canc Ctr, Northwood, Middx, England
[6] Guys & St Thomas NHS Fdn Trust, London, England
[7] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England
[8] Univ Oxford, OCTRU, Oxford, England
[9] Churchill Hosp, Dept Oncol, Oxford OX3 7LJ, England
关键词
Breast cancer; Ovarian cancer; BRCA genes; Response; 2-STAGE DESIGNS; DNA; RESISTANCE; MUTATIONS; CELLS;
D O I
10.1186/1471-2407-14-983
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AGO14699, even after these cells had acquired resistance to a PARP inhibitor or cisplatin. Exploiting the genetic basis of these tumours enables us to develop a more tailored approach to therapy for patients with BRCA mutated cancers. Methods: This multi-centre phase II single arm trial was designed to investigate the activity and safety of 6-mercaptopurine (6MP) 55 mg/m(2) per day, and methotrexate 15 mg/m(2) per week in patients with advanced breast or ovarian cancer, ECOG PS 0-2, progressing after >= one prior regimen and known to bear a BRCA1/2 germ line mutation. Accrual was planned in two stages, with treatment continuing until progression or unacceptable toxicity; in the first, if less than 3/30 evaluable patients respond at 8 weeks after commencing treatment, the trial will be stopped for futility; if not, then accrual would proceed to a second stage, in which if more than 9/65 evaluable patients are found to respond at 8 weeks, the treatment will be regarded as potentially effective and a phase III trial considered subject to satisfactory safety and tolerability. The primary outcome is objective response at 8 weeks, defined by RECISTS v1.1 as complete response, partial response or stable disease. Secondary outcomes include safety, progression-free and overall survival, and quality of life. Discussion: This study aims to investigate whether 6MP might be an effective treatment for BRCA deficient tumours even after the development of resistance to PARP inhibitors or platinum drugs. The study has surpassed the first stage analysis criteria of more than 3 out of 30 evaluable patients responding at 8 weeks, and is currently in the second stage of recruitment.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] DRUG INTERFERENCE IN ONCOLOGY - CHANGES IN KINETICS OF 6-MERCAPTOPURINE (6-MP) IN ANIMALS PREVIOUSLY TREATED WITH METHOTREXATE (MTX)
    PANNUTI, F
    LIGABUE, A
    TRASARTI, F
    BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE, 1972, 48 (19): : 574 - 576
  • [42] Prevalence and Predictors of Non-Adherence to 6-Mercaptopurine (6MP) in Children with Acute Lymphoblastic Leukemia (ALL) - a Children's Oncology Group Study.
    Bhatia, Smita
    Villaluna, Doojduen
    Landier, Wendy
    Schaible, Alexandra
    Hageman, Lindsey
    Hanby, Cara
    Leisenring, Wendy
    Hunger, Stephen P.
    Robison, Leslie L.
    Relling, Mary V.
    Wong, F. Lennie
    BLOOD, 2008, 112 (11) : 333 - 333
  • [43] IDENTIFICATION OF (35-S) 6-MERCAPTOPURINE (6MP) METABOLITES USING HIGH-PRESSURE LIQUID CATION-EXCHANGE CHROMATOGRAPHY
    BRETER, HJ
    ZAHN, RK
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1977, 297 : R5 - R5
  • [44] A PHASE-II TRIAL OF CONTINUOUS-INFUSION 6-MERCAPTOPURINE FOR CHILDHOOD SOLID TUMORS
    ADAMSON, PC
    ZIMM, S
    RAGAB, AH
    STEINBERG, SM
    BALIS, F
    KAMEN, BA
    VIETTI, TJ
    GILLESPIE, A
    POPLACK, DG
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (05) : 343 - 344
  • [45] EFFECT OF ADENOSINE (ADO) AND ITS METABOLITES ON PLASMA ACTH AND CORTICOSTERONE CONCENTRATION (PCC) IN ALLOPURINOL (AP) OR 6-MERCAPTOPURINE (6MP) PRETREATED RATS
    SZABO, J
    KOSA, E
    BRUCKNER, G
    FASEB JOURNAL, 1994, 8 (04): : A296 - A296
  • [46] COMBINED USE OF 6-MERCAPTOPURINE (6MP) AND 6-(METHYLMERCAPTO)PURINE RIBONUCLEOSIDE (ME6MPR) - SYNERGISTIC INHIBITORY EFFECTS AGAINST CULTURED LYMPHOMA CELLS
    PATERSON, AR
    MORIWAKI, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1968, 9 (MAR): : 57 - &
  • [47] 6-MERCAPTOPURINE (6-MP) METABOLITE MEASUREMENT IN IBD PATIENTS NEUTROPHILS CORRELATES WITH DRUG EFFICACY
    CUFFARI, C
    SEIDMAN, E
    THEORET, Y
    GASTROENTEROLOGY, 1995, 108 (04) : A803 - A803
  • [48] RANDOMIZED CLINICAL TRIAL OF DAUNORUBICIN AND A COMBINATION OF PREDNISONE, VINCRISTINE, 6-MERCAPTOPURINE, AND METHOTREXATE IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA
    WIERNIK, PH
    SERPICK, AA
    CANCER RESEARCH, 1972, 32 (10) : 2023 - &
  • [49] SIGNIFICANT DOSE REDUCTION IN MERCAPTOPURINE (6MP) AND METHOTREXATE (MTX) REQUIRED IN CHILDREN WITH ALL FROM TWO POPULATIONS IN ASIA
    Mohamed, Gaafar
    Belgaumi, Asim
    Fadoo, Zehra
    Wani, Tariq
    Fayea, Najwa
    Almanjomi, Fahad
    Ballourah, Walid
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [50] METHOTREXATE (MTX) - PHARMACOLOGY IN PATIENTS RECEIVING INTENSIVE MTX/6MERCAPTOPURINE (6MP) CONSOLIDATION FOR ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - A PEDIATRIC ONCOLOGY GROUP-STUDY
    GRAHAM, M
    CAMITTA, B
    LAUER, S
    LEVENTHAL, B
    CASPER, J
    CIVIN, C
    CHEO, D
    ZUHARUK, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 226 - 226